GLOBAL INTERSTITIAL CYSTITIS, BLADDER PAIN SOCIETY

Volume 8 Issue 11 || November 2026

GIBS News Letter

GLP-1 Receptor Agonists in Bladder Pain Syndrome: A Metabolic–Neuroinflammatory Frontier in Pelvic Pain Medicine

Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) remains among the most challenging disorders encountered in urogynecology and pelvic pain medicine. Characterized by chronic pelvic pain, urinary urgency, frequency, and substantial quality-of-life impairment, BPS continues to frustrate clinicians due to its heterogeneity and inconsistent treatment outcomes. Increasingly, BPS is no longer viewed as an isolated bladder disorder, but rather as a systemic neuro-inflammatory condition involving urothelial dysfunction, altered immune signaling, neurogenic inflammation, and central sensitization. This conceptual shift has prompted growing interest in therapies that target broader systemic mechanisms rather than local bladder pathology alone.(1-4)

Against this backdrop, glucagon-like peptide-1 (GLP-1) receptor agonists—including semaglutide, liraglutide, and tirzepatide—have emerged as transformative therapies in diabetes and obesity care. While initially developed for glycemic control, these medications are now recognized to possess potent anti-inflammatory, neuroprotective, and metabolic effects extending far beyond glucose homeostasis. Such observations have generated growing interest regarding whether GLP-1 therapies may influence chronic pain states, including bladder pain syndromes.(5-9)

Latest Announcement

12th Annual Congress on IC/BPS - GIBS 2027

Lock the Date :

28th-29th August 2027

Venue :

Soon to be Announced

Theme:

Phenotype, Pathways and Precision in IC/BPS

BECOME GIBS LIFETIME MEMBER



SCAN HERE!

+91 80972 53466 info@gibsociety.com www.gibsociety.com

Why This Conversation Matters Now

The growing interest in GLP-1 therapies within pelvic pain medicine reflects several converging trends. First, global uptake of semaglutide and related agents has dramatically increased, meaning clinicians are encountering more patients already receiving these therapies for approved indications. Second, recognition of the interplay between obesity, insulin resistance, systemic inflammation, and chronic pain has intensified. Finally, anecdotal observations of improvement in urinary symptoms and pelvic pain among some patients prescribed GLP-1 agonists have prompted important clinical questions. While these observations remain hypothesis-generating, they create a compelling rationale for scientific exploration.

Mechanistic Plausibility in BPS


The biologic rationale supporting GLP-1 receptor agonists in BPS is compelling. GLP-1 signaling influences multiple pathways implicated in bladder pain biology, including inflammatory signaling, neural sensitization, oxidative stress, and epithelial integrity.

Inflammation represents one of the most important targets. Experimental work suggests GLP-1 receptor activation suppresses nuclear factor kappa-B (NF-ϰB) signaling and reduces inflammatory cytokines such as TNF-α and IL-6. These pathways are increasingly recognized as contributors to chronic pain amplification and immune dysregulation within BPS.(2,3)

Neurogenic inflammation provides another important mechanistic link. Chronic bladder pain is associated with altered sensory nerve activity and exaggerated nociceptive signaling. GLP-1 receptors are expressed within peripheral nerves and central pain pathways, raising the possibility that these therapies may reduce neuronal excitability and dampen pain amplification.

Urothelial dysfunction, a hallmark of BPS, may also theoretically improve. Emerging work suggests GLP-1 signaling can reduce oxidative stress and support epithelial integrity in multiple tissues. Whether similar benefits occur within bladder epithelium remains unknown but biologically plausible.(2,3)

Figure 1. Proposed Mechanistic Pathways of GLP-1 in BPS



Preclinical and Translational Evidence

Animal studies provide early support for biologic plausibility. Rodent models have demonstrated reductions in oxidative stress markers, improved bladder histology, and modulation of sensory signaling following GLP-1 receptor activation. Neuropathic pain studies outside the bladder context have also shown reductions in hyperalgesia and mechanical allodynia, further strengthening translational interest.(5,6)

However, translation from animal models to BPS populations remains challenging. Existing studies frequently rely on models of bladder inflammation or ischemia that incompletely replicate the clinical heterogeneity of BPS.

One of the strongest human signals is reduction in inflammatory biomarkers. In exploratory analyses of the STEP 1–3 trials, semaglutide 2.4 mg reduced C-reactive protein (CRP) by approximately 39–48% versus placebo at week 68. (7) Reductions in

CRP tracked with improvements in body weight, waist circumference and insulin resistance, suggesting that some of the anti-inflammatory effect is mediated through improved metabolic state rather than a purely direct pharmacological action.

A 2024 systematic review and meta-analysis of 13 randomized trials involving 26,131 participants similarly found significantly lower CRP with semaglutide than placebo or active controls. (8) These findings do not establish relevance to BPS, but they strengthen the biological premise that GLP-1RA therapy can alter systemic inflammatory burden.

The nervous system is another potential bridge. Reviews of GLP-1 biology describe effects on neuroinflammation, oxidative stress, microglial signalling and neuronal survival.(6,9) A 2024 systematic review of GLP-1RAs in pain disorders identified signals across inflammatory pain, osteoarthritis, headache, neuropathic pain and visceral pain, while emphasizing the limitations of the clinical evidence.(10) A 2025 review similarly concluded that GLP-1RAs are promising candidates for pain research, but that better mechanistic and clinical trials are required.(11)
Furthermore, no randomized controlled trials currently evaluate semaglutide or related agents specifically in bladder pain syndrome.

Phenotype-Driven use of GLP-1

BPS is increasingly recognized as a heterogeneous disorder requiring individualized care. Future studies may benefit from identifying candidate phenotypes most likely to respond to GLP-1 therapy. Patients with obesity, insulin resistance, widespread pain syndromes, or strong central sensitization features may theoretically derive the greatest benefit.

This aligns with modern approaches to precision medicine, where therapies are selected based on biologic plausibility rather than symptom labels alone. Integrating metabolic medicine into pelvic pain care may ultimately redefine multidisciplinary management paradigms.

Current Clinician Perspective

Despite promising signals, enthusiasm must remain balanced with scientific caution. At present, GLP-1 receptor agonists should not be viewed as established therapies for BPS. Important unanswered questions remain regarding dose, duration, safety, ideal patient selection, and rebound symptoms after stopping therapy.

Potential adverse effects—including nausea, constipation, dehydration, and delayed gastric emptying—may hold relevance in BPS populations. Even though benefits in symptom relief may be plausible during the use of GLP-1, how these change when GLP-1 is stopped is yet to be understood. Do the symptoms remain suppressed or is there rebound increase in inflammation worsening pain? Moreover, concerns around accessibility and cost require thoughtful consideration.

For now, the most reasonable clinical approach may involve careful observation of patients already prescribed GLP-1 agents for approved metabolic indications. Structured reporting of symptom trajectories could generate valuable real-world evidence.

Key Clinical Takeaways

- BPS/IC increasingly appears to involve systemic neuro-immune mechanisms.
- GLP-1 receptor agonists possess anti-inflammatory and neuroprotective effects relevant to pelvic pain biology.
- Current evidence remains preliminary and hypothesis-generating.
- Phenotype-based approaches may identify subgroups most likely to benefit.
- Rigorous randomized trials remain urgently needed.

Conclusion

GLP-1 receptor agonists represent an intriguing metabolic–neuroinflammatory frontier in pelvic pain medicine. Whether these therapies ultimately emerge as transformative adjuncts in bladder pain syndrome—or remain biologically compelling but clinically limited—will depend on the rigor of future investigation. For clinicians and researchers within the GIBS community, the challenge now lies not in enthusiasm alone, but in designing the careful science necessary to determine whether this promising signal translates into meaningful clinical benefit.

References:

1. Tornic J, Engeler D. Latest insights into the pathophysiology of bladder pain syndrome/interstitial cystitis. Curr Opin Urol. 2024;34(2):84- 88. doi:10.1097/MOU.0000000000001158.
2. Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2022;208(1):34-42. doi:10.1097/JU.0000000000002756.
3. Jhang JF, Yu WR, Jiang YH, Kuo HC. Pathophysiology and potential multimodal therapeutic strategies for IC/BPS. Nat Rev Urol. 2025;22:672-686. doi:10.1038/s41585-025-01044-4.
4. Mohammad A, Laboulaye MA, Shenhar C, Dobberfuhl AD. Mechanisms of oxidative stress in interstitial cystitis/bladder pain syndrome. Nat Rev Urol. 2024;21(7):433-449. doi:10.1038/s41585-023-00850-y.
5. Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni V, et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022;182:106320. doi:10.1016/j.phrs.2022.106320.
6. Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res. 2022;186:106550. doi:10.1016/j.phrs.2022.106550.
7. Verma S, Bhatta M, Davies M, Deanfield JE, Garvey WT, Jensen C, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. EClinicalMedicine. 2022;55:101737. doi:10.1016/j.eclinm.2022.101737.
8. Masson W, Lobo M, Nogueira JP, Rodriguez-Granillo AM, Barbagelata LE, Siniawski D. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1379189. doi:10.3389/fcvm.2024.1379189.
9. Halloum W, Al Dughem Y, Beier D, Pellesi L. Glucagon-like peptide-1 receptor agonists for headache and pain disorders: a systematic review. J Headache Pain. 2024;25(1):112. doi:10.1186/s10194-024-01821-3.
10. He Y, Xu B, Zhang M, Chen D, Wu S, Gao J, et al. Advances in GLP-1 receptor agonists for pain treatment and their future potential. J Headache Pain. 2025;26(1):46. doi:10.1186/s10194-025-01979-4.
11. Jhang JF, Jiang YH, Kuo HC. Current understanding of the pathophysiology and novel treatments of interstitial cystitis/bladder pain syndrome. Biomedicines. 2022;10(10):2380. doi:10.3390/biomedicines10102380.
12. Verma S, et al. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol. 2022;21:160. doi:10.1186/s12933-022-01585-7.
13. Park JJ, Kim KT, Lee EJ, Chun J, Lee S, Shim SR, Kim JH. Current updates relating to treatment for interstitial cystitis/bladder pain syndrome: systematic review and network meta-analysis. BMC Urol. 2024;24:95. doi:10.1186/s12894-024-01485-w.



Author

Dr. Latika Chawla

Consultant Gynaecologist & Endoscopic Surgeon, Endometriosis Excision Surgeon, Mumbai. Lilavati Hospital, Surya Hospital, GIBS Core Member

BE THE NEXT NEWSLETTER AUTHOR

Please send your contributions to info@gibsociety.com

GLOBAL INTERSTITIAL CYSTITIS
BLADDER PAIN SOCIETY

GIBS Periodic Case-Based Discussion Webinar, India

Topic Theme:
The Evolving Paradigm of a Pain Syndrome

The Webinar Organised by GMC Hospital, Srinagar, Brought Together Distinguished National and International Experts to Discuss the Complexities of Bladder Pain Syndrome (BPS) following Intravesical BCG Therapy in a Patient with Superficial Transitional Cell Carcinoma (TCC) of the Bladder.

Date:
16th October 2026

Time:
7:30 PM - 8:30 PM IST

Organizing Chairperson & Scientific Speaker

Prof. (Dr.) Syed Sajjad Nazir

Delivered a Scientific Presentation on "Management of Severe BPS Following Intravesical BCG in a Patient with Superficial TCC Bladder," exploring the clinical challenges and management considerations in this complex case.

Case-Based Presenter

Dr. Syed Yasir Quadri

Presented the Case, Encouraging Discussion on Diagnosis and Treatment.


Expert Panel Discussion

Dr. Syed Yasir Quadri

Dr. Bhojraj Luitel, Dr. Cindy Zietsman, Dr. Sanjay Chincholikar and Prof. Dr. Shingai Mutambirwa shared valuable clinical insights.

Key Learning Message

The Session Highlighted the Complexities of Severe Bladder Pain following Intravesical BCG Therapy and the Importance of Careful Clinical Evaluation, Individualised Management and Evidence-Informed Decision Making in Challenging BPS Cases.



Acknowledgement

GIBS Thanks the Organising Chairperson, All Faculty Members, Panelists and Participants for Making this an Enriching Learning Experience.

+91 80972 53466 info@gibsociety.com www.gibsociety.com

DON'T MISS OUT

Take part in shaping the future through knowledge, collaboration and shared expertise.

Latest Webinar Updates

UTI or BPS?
The Diagnostic Dilemma

Organizing Chairperson - Dr. Amita Jain, Delhi

Nov 20, 2026 | **07:30 PM**

PLATFORM

ZOOM

REGISTER NOW!!

https://us06web.zoom.us/webinar/register/WN_QQk1T8AMQTqo9mohzGQe9Q

GLOBAL INTERSTITIAL CYSTITIS
BLADDER PAIN SOCIETY

GIBS 2027

ANNOUNCING

28th-29th AUGUST 2027

Theme:

Phenotypes, Pathways to Precision in IC/BPS



VENUE : MUMBAI, INDIA
(Location To Be Announced)

Become a Lifetime Member and
Avail Discounts on GIBS 2027 Registration

info@gibsociety.com